In this regard, in a mouse model of Lewis lung cancer, IDO inhibition by oral administration of 1-MT synergizes with radiotherapy by reducing the expression of PD-1/PD-L1, TIM-3, BTLA, and Gal-9 to restore antitumor immune response and inhibit tumor progression (197). The gene discussed is HAVCR2; the disease is neoplasm.